Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases.

Mishra, N; Ashique, S; Garg, A; Rai, VK; Dua, K; Goyal, A; Bhatt, S

Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases.

Mishra, N Ashique, S Garg, A Rai, VK Dua, K

Goyal, A Bhatt, S

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Drug Discov Today, 2022
Issue Date:: 2022-01-10

Closed Access

	Filename	Description	Size
	siRNA_Nanocarriers_1-s2.0-S1359644622000034-main.pdf	Published version	1.35 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Mishra, N
dc.contributor.author	Ashique, S
dc.contributor.author	Garg, A
dc.contributor.author	Rai, VK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Goyal, A
dc.contributor.author	Bhatt, S
dc.date.accessioned	2022-01-18T21:56:54Z
dc.date.available	2022-01-05
dc.date.available	2022-01-18T21:56:54Z
dc.date.issued	2022-01-10
dc.identifier.citation	Drug Discov Today, 2022
dc.identifier.issn	1359-6446
dc.identifier.issn	1878-5832
dc.identifier.uri	http://hdl.handle.net/10453/153283
dc.description.abstract	Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Drug Discov Today
dc.relation.isbasedon	10.1016/j.drudis.2022.01.003
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.title	Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-01-18T21:56:52Z
pubs.publication-status	Published online

Abstract:

Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/153283